Top Stock Ideas Sent Daily — Join and Gain Your Edge

+ New Watchlist

Benzinga Research

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Pasithea Therapeutics

KTTAWNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.025500

0.00041.48%

At Close: -

$0.033000

0.007529.41%

After Hours: Oct 2, 5:11 PM EDT

15 minutes delayed

Pasithea Therapeutics (KTTAW) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Pasithea Therapeutics (NASDAQ:KTTAW) Stock

Pasithea Therapeutics Stock (NASDAQ: KTTAW)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, September 27, 2024

Pasithea Therapeutics Priced $5M Private Plac...
Benzinga Newsdesk

Tuesday, January 02, 2024

Trading Halt: Halt status updated at 9:00:00 ...
Benzinga Newsdesk

Saturday, December 30, 2023

Trading Halt: Halted at 7:50:00 p.m. ET - Tra...
Benzinga Newsdesk

Thursday, August 11, 2022

EXCLUSIVE: Pasithea Says 'PAS002 effectively ...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics Announces Re...
Benzinga Newsdesk

Thursday, June 23, 2022

EXCLUSIVE: Pasithea Therapeutics CEO, Tiago R...
Benzinga Newsdesk

Wednesday, June 22, 2022

EXCLUSIVE: Pasithea Therapeutics Acquires Alp...
Benzinga Newsdesk

Tuesday, March 08, 2022

EXCLUSIVE: Pasithea Therapeutics Announces Co...
Benzinga Newsdesk

Thursday, February 03, 2022

Pasithea Therapeutics Says 'Company Commences...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics Initiates Ne...
Benzinga Newsdesk

Thursday, December 23, 2021

EXCLUSIVE: Pasithea Therapeutics CEO Says 'We...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO Notes Co...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO, When As...
Benzinga Newsdesk

Tuesday, December 21, 2021

EXCLUSIVE: Pasithea Therapeutics' Pasithea Ha...
Benzinga Newsdesk

Tuesday, November 23, 2021

Ault Global Holdings Founder Tweets '"Today w...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO, Tiago R...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO, Tiago R...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO, Tiago R...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics CEO, Tiago R...
Benzinga Newsdesk
EXCLUSIVE: Pasithea Therapeutics' Subsidiary ...
Benzinga Newsdesk

Wednesday, November 17, 2021

EXCLUSIVE: Pasithea Therapeutics Says 'Ketami...
Zoltan Suranyi
EXCLUSIVE: Pasithea Therapeutics' Wholly Owned Subsidiary Pasithea Clinics To Launch In-Home Intravenous Ketamine Therapy In New York City, Los Angeles, San Diego, And San Francisco To Expand Its International Footprint
Zoltan Suranyi

Wednesday, October 27, 2021

EXCLUSIVE: Pasithea Therapeutics's Subsidiary...
Benzinga Newsdesk

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved